CA2799227C - Extracorporeal devices and methods of treating complications of pregnancy - Google Patents

Extracorporeal devices and methods of treating complications of pregnancy Download PDF

Info

Publication number
CA2799227C
CA2799227C CA2799227A CA2799227A CA2799227C CA 2799227 C CA2799227 C CA 2799227C CA 2799227 A CA2799227 A CA 2799227A CA 2799227 A CA2799227 A CA 2799227A CA 2799227 C CA2799227 C CA 2799227C
Authority
CA
Canada
Prior art keywords
agent
sflt
subject
level
pregnancy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2799227A
Other languages
English (en)
French (fr)
Other versions
CA2799227A1 (en
Inventor
S. Ananth Karumanchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of CA2799227A1 publication Critical patent/CA2799227A1/en
Application granted granted Critical
Publication of CA2799227C publication Critical patent/CA2799227C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2799227A 2010-05-14 2011-05-13 Extracorporeal devices and methods of treating complications of pregnancy Active CA2799227C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33482410P 2010-05-14 2010-05-14
US61/334,824 2010-05-14
US34621610P 2010-05-19 2010-05-19
US61/346,216 2010-05-19
PCT/US2011/036409 WO2011143538A1 (en) 2010-05-14 2011-05-13 Extracorporeal devices and methods of treating complications of pregnancy

Publications (2)

Publication Number Publication Date
CA2799227A1 CA2799227A1 (en) 2011-11-17
CA2799227C true CA2799227C (en) 2020-06-16

Family

ID=44911968

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2799227A Active CA2799227C (en) 2010-05-14 2011-05-13 Extracorporeal devices and methods of treating complications of pregnancy

Country Status (7)

Country Link
US (2) US8969322B2 (https=)
EP (3) EP3248946B1 (https=)
JP (2) JP5959506B2 (https=)
CN (1) CN102884006B (https=)
AU (1) AU2011252954B2 (https=)
CA (1) CA2799227C (https=)
WO (1) WO2011143538A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011252954B2 (en) 2010-05-14 2015-04-16 Beth Israel Deaconess Medical Center Extracorporeal devices and methods of treating complications of pregnancy
US8979787B2 (en) * 2011-01-20 2015-03-17 Henry John Smith Treatment of pre-eclampsia using targeted apheresis
MX2015010174A (es) * 2013-02-08 2016-03-31 Univ Iowa Res Found Herramientas de diagnostico para predecir la presentacion de preeclampsia.
KR20160102440A (ko) * 2013-12-27 2016-08-30 엘리아스 세라퓨틱스 인코포레이티드 혈장 분리 반출 장치
EP3097422B1 (en) 2014-01-24 2018-07-11 Roche Diagnostics GmbH Prediction of postpartum hellp syndrome, postpartum eclampsia or postpartum preeclampsia
US11383015B2 (en) * 2016-01-11 2022-07-12 Fenwal, Inc. System and method for plasma purification prior to mononuclear cell collection
CN108883193A (zh) 2016-03-31 2018-11-23 伊穆特丽克斯治疗股份有限公司 先兆子痫和有关障碍的体外治疗方法
WO2019026870A1 (ja) * 2017-08-01 2019-02-07 学校法人学文館 ｓＦｌｔ－１（可溶型血管内皮増殖因子受容体－１）の新規測定法
US20200264188A1 (en) * 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
WO2020061590A1 (en) * 2018-09-21 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Methods for evaluation of gestational progress and preterm abortion for clinical intervention and applications thereof
EP3669888B1 (en) 2018-12-20 2025-09-24 Gambro Lundia AB Extracorporeal devices for methods for treating diseases associated with anti-neutrophil cytoplasmic antibodies
JP7526737B2 (ja) 2019-03-06 2024-08-01 ガンブロ ルンディア アクティエボラーグ アルカリホスファターゼを含む血液処理装置
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery
WO2024232421A1 (ja) 2023-05-11 2024-11-14 タグシクス・バイオ株式会社 可溶性ｆｌｔ－１に選択的に結合するｄｎａアプタマーおよびそのｄｎａアプタマーが固定化された担体
WO2025240713A1 (en) * 2024-05-17 2025-11-20 Aslam Shakil Method for treating pre-eclampsia with stationary phase heparin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US4994161A (en) * 1989-02-02 1991-02-19 University Of New Hampshire Apparatus and method for macromolecular charge determination
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
AU4410296A (en) 1994-11-29 1996-06-19 Duke University Diagnosis of and therapy for hereditary haemorrhagic telangiectasia
EP1016726A1 (en) 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
DE10117043A1 (de) 2001-04-05 2002-11-07 Gerhard Puetz Verfahren zur Eliminierung von potentiell toxischen und/oder schädlichen Stoffen
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
ES2534926T3 (es) 2002-07-19 2015-04-30 Beth Israel Deaconess Medical Center Métodos para tratar la preeclampsia
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
SG155257A1 (en) 2004-09-24 2009-09-30 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US20060067931A1 (en) 2004-09-25 2006-03-30 Hazel Lum Receptor for lysophosphatidylcholine in vascular endothelial cells and use thereof
EP1839056B1 (en) * 2004-12-21 2011-08-03 Yale University Diagnosis of preeclampsia
US20060153835A1 (en) * 2005-01-12 2006-07-13 Smith Henry J Treatment of pre-eclampsia in pregnant women using targeted apheresis
MX2008015197A (es) 2006-05-31 2009-06-23 Beth Israel Hospital Metodos de diagnosticar y tratar las complicaciones del embrazo.
US20090286271A1 (en) 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
PH12012500781A1 (en) * 2009-11-09 2015-03-04 Zeiss Carl Vision Int Gmbh Ophthalmic lens element
AU2011252954B2 (en) 2010-05-14 2015-04-16 Beth Israel Deaconess Medical Center Extracorporeal devices and methods of treating complications of pregnancy

Also Published As

Publication number Publication date
EP3248946A1 (en) 2017-11-29
EP2706041B1 (en) 2018-10-03
CN102884006B (zh) 2016-02-17
EP2569253A4 (en) 2013-10-02
US20110280825A1 (en) 2011-11-17
WO2011143538A1 (en) 2011-11-17
JP5959506B2 (ja) 2016-08-02
CN102884006A (zh) 2013-01-16
EP2706041A1 (en) 2014-03-12
JP2016147065A (ja) 2016-08-18
US8969322B2 (en) 2015-03-03
JP2013532129A (ja) 2013-08-15
EP2569253A1 (en) 2013-03-20
CA2799227A1 (en) 2011-11-17
US9925211B2 (en) 2018-03-27
US20150132250A1 (en) 2015-05-14
AU2011252954A1 (en) 2012-11-22
EP3248946B1 (en) 2021-02-24
AU2011252954B2 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
CA2799227C (en) Extracorporeal devices and methods of treating complications of pregnancy
Feld et al. Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment
JP5105687B2 (ja) 高活性および低減された副作用を有する組換えエリスロポエチンの治療的使用
JP6169495B2 (ja) 妊娠関連高血圧性障害を治療または予防するための方法およびシステム
JP2013532129A5 (https=)
CN101842111A (zh) 选择性细胞隔离装置及其相关方法
Stefoni et al. Standard heparin versus low-molecular-weight heparin: a medium-term comparison in hemodialysis
EP2622354A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
EP2834642A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
Xu et al. Effects of early hemofiltration on organ function and intra-abdominal pressure in severe acute pancreatitis patients with abdominal compartment syndrome
RU2420534C2 (ru) Способ получения обедненного молекулами стабилизаторов водного раствора альбумина, адсорбент и его применение в способе, применение водного раствора альбумина (варианты)
Klinkmann et al. Therapeutic apheresis in sepsis
HK1189566A (en) Extracorporeal devices and methods of treating complications of pregnancy
WO2012093681A1 (ja) 敗血症治療薬を投与する患者を選択する方法
JP2024536529A (ja) 全血のアフェレーシス
KR20040004681A (ko) 혈관재생 요법
EP1948216B1 (en) Treatment of acute renal failure with soluble thrombomodulin
JP2012519674A (ja) フィブリノーゲンの新規な使用
Jiang et al. The Effect of Heparin-Grafted Chitosan-Cellulose Composite Microspheres on the Removal of Endotoxins and Circulating Histones in a Septic Rabbit Model: An In Vivo Study
Sakurai et al. Effects of the Fluid Replacement Method During Online Hemodiafiltration on the Solute Removal Performance and Biocompatibility Using the Asymmetric Cellulose Triacetate Membrane
RU2196589C2 (ru) Способ индукции рассасывания образовавшихся рубцов или фиброзных образований в кровеносных сосудах или в сосудистой сети млекопитающего
WO2021113696A1 (en) Methods for controlling extracorporeal membrane oxygenation (ecmo) coagulation
Hothi et al. Common complications of haemodialysis
Xue Treatment of Metabolic Diseases by Hemoperfusion

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160419

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509